Document is current
Any future updates will be listed below
-
Authors
Wijesinghe, Sharanya K. M. https://orcid.org/0000-0002-0798-6226
Rausch, Lisa
Gabriel, Sarah S. https://orcid.org/0000-0002-6359-485X
Galletti, Giovanni https://orcid.org/0000-0001-6613-2354
De Luca, Marco https://orcid.org/0000-0001-8310-5526
Qin, Lei
Wen, Lifen https://orcid.org/0000-0003-0229-7306
Tsui, Carlson https://orcid.org/0000-0003-0642-814X
Man, Kevin https://orcid.org/0000-0002-6585-9532
Heyden, Leonie https://orcid.org/0009-0001-2018-8747
Mason, Teisha
Newland, Lewis D. https://orcid.org/0009-0004-0327-8910
Kueh, Andrew
Liao, Yang https://orcid.org/0000-0002-9746-2839
Chisanga, David https://orcid.org/0000-0002-0421-3957
Swatler, Julian https://orcid.org/0000-0001-8710-2808
Voulaz, Emanuele
Marulli, Giuseppe
Errico, Valentina
Losurdo, Agnese
Rossi, Gustavo R.
Souza-Fonseca-Guimaraes, Fernando https://orcid.org/0000-0002-2037-8946
Huntington, Nicholas D. https://orcid.org/0000-0002-5267-7211
Gebhardt, Thomas https://orcid.org/0000-0002-3768-9468
Utzschneider, Daniel T. https://orcid.org/0000-0003-2205-9057
Herold, Marco J.
Shi, Wei
Schroeder, Jan
Lugli, Enrico https://orcid.org/0000-0002-1964-7678
Kallies, Axel https://orcid.org/0000-0002-6312-6968
- License Information
-
More Information
Article History
Received: 7 April 2025
Accepted: 12 June 2025
First Online: 29 July 2025
Competing interests
: A.K. receives research support from Pfizer. N.D.H. is a founder and shareholder in oNKo-Innate and serves on advisory boards for Bristol Myers Squibb and Syena. T.G. was a scientific advisory board member of oNKo-Innate and received research funding from Merck Healthcare KGaA. E.L. is listed as the inventor on a patent on TSCM cells and received royalties related to that patent, received research funding from Bristol Myers Squibb on a topic unrelated to this paper and reports consulting fees from BD Biosciences, BioLegend, Swarm Oncology, Pfizer, Menarini and Astra Zeneca. All other authors declare no competing interests.
